Healthcare

Dassault Systemes SE, a maker of industrial design software, agreed to buy Medidata Solutions Inc. for $5.7 billion to gain a foothold in the fast-growing market for clinical trial technology. Medidata offers clients wearable sensors that help track patient health and biomarker analysis to select which patients may best respond to certain drugs. It estimates that 13 of the top 15 medicines sold last year relied on its technology, as the healthcare industry shifts towards personalized medicine and the targeting of individual patient profiles.

Beyhan Zaim '94, a Healthcare and Pharmaceutical Advisory Board member at CBS, joins Novo Nordisk as Senior Vice President of Commercial Business Development.  

Dr. Geraldine McGinty '00, chief strategy officer of Weill Cornell Medicine’s Physician Organization, has been named the 2019 recipient of the Jessica M. and Natan Bibliowicz Award for Excellence in Mentoring Women Faculty.

A series of research papers from Columbia Business School show how hospitals can reduce costs by examining their patient efficiency strategies

The cost of medicines is a major topic of concern for all healthcare stakeholders. Yet it's incredibly hard to understand the opaque world of drug pricing, its cost to the system and impact on patients. This event was part of a new and exciting cross campus initiative to engender debate and demand clarity on important healthcare issues and topics through the intersection between theory and practice. 

New research from Columbia Business School casts light on ways to remedy the project shortfall of more than 121,000 physicians by 2030

Tom DeRosa ’88, CEO of Welltower, a member of the School’s Board of Overseers and HPM Advisory Board, has created an endowed fund to support the Healthcare and Pharmaceutical Management Program at Columbia Business School.

Kenneth Frazier, CEO of Merck & Co., Inc., broke away from the earnings guidance from shareholders and continued the core commitment to research, substantially refocusing the organization on the launch and growth of products that benefit the public for the long term.

Laurence Coman ’20, Seth Goodman ’19 and Rotem Lev-Zwickel ’18 selected to participate in ELabNYC Bioscience Accelerator Program for 2019 Cohort

Isaiah Einzig '20 spoke to Matthew Price '09, Executive Vice President & COO of Phosplatin Therapeutics, about his entrepreneurship journey in the life science industry starting with his time at CBS.